<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492958</url>
  </required_header>
  <id_info>
    <org_study_id>B3451003</org_study_id>
    <secondary_id>6123K1-1006</secondary_id>
    <nct_id>NCT02492958</nct_id>
  </id_info>
  <brief_title>SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults</brief_title>
  <official_title>A Phase 1/2a Placebo-controlled, Randomized, Double-blind, Sponsor-unblinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Japanese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of a
      single dose of Staphylococcus aureus 4 antigen vaccine in Japanese adults aged 20 to &lt;86
      years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants reporting local reactions (size of redness and/or swelling and severity of pain at the injection site) and severity of the local reactions as self-reported on electronic diaries</measure>
    <time_frame>14 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting systemic events (fever, fatigue, headache, vomiting, diarrhea, muscle pain, and joint pain) and severity of systemic events as self-reported on electronic diaries</measure>
    <time_frame>14 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting adverse events, newly diagnosed chronic medical disorders, and serious adverse events categorized according to the Medical Dictionary for Regulatory Activities</measure>
    <time_frame>12 month after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Phase 1 participants with grading shifts in hematology, coagulation, and blood chemistry laboratory assessments</measure>
    <time_frame>15 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Phase 1 participants with abnormal hematologic, coagulation, and blood chemistry assessments</measure>
    <time_frame>15 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving antibody responses to specific vaccine components with results ≥ thresholds defined for each vaccine component based on immunoglobulin-binding, opsonophagocytic activity and fibrinogen binding assays.</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Primary Immunogenicity Endpoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers specific to each vaccine component at each applicable blood sampling time pointe based on immunoglobulin-binding, opsonophagocytic activity and fibrinogen binding assays.</measure>
    <time_frame>various, up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise specific to each vaccine component at each applicable blood sampling time pointe based on immunoglobulin-binding, opsonophagocytic activity and fibrinogen binding assays.</measure>
    <time_frame>various, up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving antibody responses to specific vaccine components with results ≥ thresholds defined for each vaccine component based on immunoglobulin-binding, opsonophagocytic activity and fibrinogen binding assays.</measure>
    <time_frame>various, up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Staphylococcal Infections</condition>
  <arm_group>
    <arm_group_label>SA4Ag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Staphylococcus aureus 4-antigen vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Staphylococcus aureus 4-antigen vaccine</intervention_name>
    <description>a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm</description>
    <arm_group_label>SA4Ag</arm_group_label>
    <other_name>SA4Ag</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Japanese male and female adults aged 20 to &lt;86 years,

          2. Determined as healthy by the investigator (Subjects with preexisting chronic medical
             conditions determined to be stable may be included),

          3. Must be available for the 12 month duration of the study,

          4. Subjects must agree to use an acceptable method of birth control for 3 months after
             study vaccination (if the subject or the subject's partner are/is capable of having
             children).

        Exclusion Criteria:

          1. Any contraindication to vaccination or vaccine components, including previous
             anaphylactic reaction to any vaccine or vaccine-related components,

          2. Unstable or serious chronic medical condition that would increase the subject's risk
             of participation,

          3. Immune system suppression or treatment with medications that suppress the immune
             system,

          4. Receipt of blood products or immunoglobulins within the past 12 months,

          5. Any infection proven or suspected to be caused by S.aureus within the past 6 months,

          6. A staff member at this site nor a relative of those site staff members, nor a
             sponsor's employee directly involved in the conduct of this research study,

          7. Living in a nursing home, long-term care facility or other institution or requiring
             any types of nursing care,

          8. A pregnant or a breast feeding woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Co. LTA Sumida Hospital</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Co.LTA PS Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3451003&amp;StudyName=A%20Phase%201%2F2a%20Placebo-controlled%2C%20Randomized%2C%20Double-blind%2C%20Sponsor-unblinded%20Trial%20To%20Evaluate%20The%20Safety%2C%20Tolerability%2C%20And%20Immunogenicity%20Of%20Staphylococcus%20Aureus%204-antigen%20Vaccine%20%28sa4ag%29%20In%20Japanese%20Adults</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <last_update_submitted>October 5, 2016</last_update_submitted>
  <last_update_submitted_qc>October 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 15, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>September 28, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

